260 related articles for article (PubMed ID: 26668209)
1. Evaluation of Ketoconazole and Its Alternative Clinical CYP3A4/5 Inhibitors as Inhibitors of Drug Transporters: The In Vitro Effects of Ketoconazole, Ritonavir, Clarithromycin, and Itraconazole on 13 Clinically-Relevant Drug Transporters.
Vermeer LM; Isringhausen CD; Ogilvie BW; Buckley DB
Drug Metab Dispos; 2016 Mar; 44(3):453-9. PubMed ID: 26668209
[TBL] [Abstract][Full Text] [Related]
2. Clinical CYP3A inhibitor alternatives to ketoconazole, clarithromycin and itraconazole, are not transported into the liver by hepatic organic anion transporting polypeptides and organic cation transporter 1.
Higgins JW; Ke AB; Zamek-Gliszczynski MJ
Drug Metab Dispos; 2014 Nov; 42(11):1780-4. PubMed ID: 25106415
[TBL] [Abstract][Full Text] [Related]
3. Ritonavir is the best alternative to ketoconazole as an index inhibitor of cytochrome P450-3A in drug-drug interaction studies.
Greenblatt DJ; Harmatz JS
Br J Clin Pharmacol; 2015 Sep; 80(3):342-50. PubMed ID: 25923589
[TBL] [Abstract][Full Text] [Related]
4. Drug-Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies.
Zurth C; Koskinen M; Fricke R; Prien O; Korjamo T; Graudenz K; Denner K; Bairlein M; von Bühler CJ; Wilkinson G; Gieschen H
Eur J Drug Metab Pharmacokinet; 2019 Dec; 44(6):747-759. PubMed ID: 31571146
[TBL] [Abstract][Full Text] [Related]
5. Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.
Oshida K; Shimamura M; Seya K; Ando A; Miyamoto Y
Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):117-128. PubMed ID: 26961540
[TBL] [Abstract][Full Text] [Related]
6. Itraconazole and clarithromycin as ketoconazole alternatives for clinical CYP3A inhibition studies.
Ke AB; Zamek-Gliszczynski MJ; Higgins JW; Hall SD
Clin Pharmacol Ther; 2014 May; 95(5):473-6. PubMed ID: 24747234
[TBL] [Abstract][Full Text] [Related]
7. Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
Shebley M; Liu J; Kavetskaia O; Sydor J; de Morais SM; Fischer V; Nijsen MJMA; Bow DAJ
Drug Metab Dispos; 2017 Jul; 45(7):755-764. PubMed ID: 28483778
[TBL] [Abstract][Full Text] [Related]
8. Pomalidomide: evaluation of cytochrome P450 and transporter-mediated drug-drug interaction potential in vitro and in healthy subjects.
Kasserra C; Assaf M; Hoffmann M; Li Y; Liu L; Wang X; Kumar G; Palmisano M
J Clin Pharmacol; 2015 Feb; 55(2):168-78. PubMed ID: 25159194
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of
Liao M; Jaw-Tsai S; Beltman J; Simmons AD; Harding TC; Xiao JJ
Xenobiotica; 2020 Sep; 50(9):1032-1042. PubMed ID: 32129697
[TBL] [Abstract][Full Text] [Related]
10. Assessment of drug-drug interaction potential and PBPK modeling of CC-223, a potent inhibitor of the mammalian target of rapamycin kinase.
Tong Z; Narayanan R; Atsriku C; Nissel J; Li Y; Liu H; Wang X; Surapaneni S
Xenobiotica; 2019 Jan; 49(1):54-70. PubMed ID: 29297772
[TBL] [Abstract][Full Text] [Related]
11. Liver injury associated with ketoconazole: review of the published evidence.
Greenblatt HK; Greenblatt DJ
J Clin Pharmacol; 2014 Dec; 54(12):1321-9. PubMed ID: 25216238
[TBL] [Abstract][Full Text] [Related]
12.
Bleasby K; Fillgrove KL; Houle R; Lu B; Palamanda J; Newton DJ; Lin M; Chan GH; Sanchez RI
Antimicrob Agents Chemother; 2019 Apr; 63(4):. PubMed ID: 30745395
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and Drug-Drug Interaction of Ocedurenone (KBP-5074) in vitro and in vivo.
Wang P; Liu J; Tan X; Yang F; McCabe J; Zhang J
Eur J Drug Metab Pharmacokinet; 2023 Jul; 48(4):397-410. PubMed ID: 37357226
[TBL] [Abstract][Full Text] [Related]
14. Prediction of the Transporter-Mediated Drug-Drug Interaction Potential of Dabrafenib and Its Major Circulating Metabolites.
Ellens H; Johnson M; Lawrence SK; Watson C; Chen L; Richards-Peterson LE
Drug Metab Dispos; 2017 Jun; 45(6):646-656. PubMed ID: 28320730
[TBL] [Abstract][Full Text] [Related]
15. In vitro and physiologically-based pharmacokinetic based assessment of drug-drug interaction potential of canagliflozin.
Mamidi RNVS; Dallas S; Sensenhauser C; Lim HK; Scheers E; Verboven P; Cuyckens F; Leclercq L; Evans DC; Kelley MF; Johnson MD; Snoeys J
Br J Clin Pharmacol; 2017 May; 83(5):1082-1096. PubMed ID: 27862160
[TBL] [Abstract][Full Text] [Related]
16. Physiologically Based Pharmacokinetic Model of Itraconazole and Two of Its Metabolites to Improve the Predictions and the Mechanistic Understanding of CYP3A4 Drug-Drug Interactions.
Prieto Garcia L; Janzén D; Kanebratt KP; Ericsson H; Lennernäs H; Lundahl A
Drug Metab Dispos; 2018 Oct; 46(10):1420-1433. PubMed ID: 30068519
[TBL] [Abstract][Full Text] [Related]
17. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
[TBL] [Abstract][Full Text] [Related]
18. Oral coadministration of elacridar and ritonavir enhances brain accumulation and oral availability of the novel ALK/ROS1 inhibitor lorlatinib.
Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
Eur J Pharm Biopharm; 2019 Mar; 136():120-130. PubMed ID: 30660696
[TBL] [Abstract][Full Text] [Related]
19. In vitro cytochrome P450- and transporter-mediated drug interaction potential of 6β-hydroxy-21-desacetyl deflazacort-A major human metabolite of deflazacort.
Ma J; Beers B; Manohar R; Roe S; Colacino JM; Kong R
Pharmacol Res Perspect; 2021 Apr; 9(2):e00748. PubMed ID: 33749127
[TBL] [Abstract][Full Text] [Related]
20. The utility of CYP3A activity endogenous markers for evaluating drug-drug interaction between sildenafil and CYP3A inhibitors in healthy subjects.
Lee S; Kim AH; Yoon S; Lee J; Lee Y; Ji SC; Yoon SH; Lee S; Yu KS; Jang IJ; Cho JY
Drug Metab Pharmacokinet; 2021 Feb; 36():100368. PubMed ID: 33348240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]